312 related articles for article (PubMed ID: 23203689)
1. Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents.
Day JW; Gelfanov V; Smiley D; Carrington PE; Eiermann G; Chicchi G; Erion MD; Gidda J; Thornberry NA; Tschöp MH; Marsh DJ; SinhaRoy R; DiMarchi R; Pocai A
Biopolymers; 2012; 98(5):443-50. PubMed ID: 23203689
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
Pocai A; Carrington PE; Adams JR; Wright M; Eiermann G; Zhu L; Du X; Petrov A; Lassman ME; Jiang G; Liu F; Miller C; Tota LM; Zhou G; Zhang X; Sountis MM; Santoprete A; Capito' E; Chicchi GG; Thornberry N; Bianchi E; Pessi A; Marsh DJ; SinhaRoy R
Diabetes; 2009 Oct; 58(10):2258-66. PubMed ID: 19602537
[TBL] [Abstract][Full Text] [Related]
3. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
[TBL] [Abstract][Full Text] [Related]
4. DPP-IV-resistant, long-acting oxyntomodulin derivatives.
Santoprete A; Capitò E; Carrington PE; Pocai A; Finotto M; Langella A; Ingallinella P; Zytko K; Bufali S; Cianetti S; Veneziano M; Bonelli F; Zhu L; Monteagudo E; Marsh DJ; Sinharoy R; Bianchi E; Pessi A
J Pept Sci; 2011 Apr; 17(4):270-80. PubMed ID: 21294225
[TBL] [Abstract][Full Text] [Related]
5. A novel glucagon-like peptide-1/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects.
Zhou J; Cai X; Huang X; Dai Y; Sun L; Zhang B; Yang B; Lin H; Huang W; Qian H
Eur J Med Chem; 2017 Sep; 138():1158-1169. PubMed ID: 28772236
[TBL] [Abstract][Full Text] [Related]
6. The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin.
Kosinski JR; Hubert J; Carrington PE; Chicchi GG; Mu J; Miller C; Cao J; Bianchi E; Pessi A; Sinharoy R; Marsh DJ; Pocai A
Obesity (Silver Spring); 2012 Aug; 20(8):1566-71. PubMed ID: 22421924
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity.
Miranda LP; Winters KA; Gegg CV; Patel A; Aral J; Long J; Zhang J; Diamond S; Guido M; Stanislaus S; Ma M; Li H; Rose MJ; Poppe L; Véniant MM
J Med Chem; 2008 May; 51(9):2758-65. PubMed ID: 18412318
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological targeting of glucagon and glucagon-like peptide 1 receptors has different effects on energy state and glucose homeostasis in diet-induced obese mice.
Gu W; Lloyd DJ; Chinookswong N; Komorowski R; Sivits G; Graham M; Winters KA; Yan H; Boros LG; Lindberg RA; Véniant MM
J Pharmacol Exp Ther; 2011 Jul; 338(1):70-81. PubMed ID: 21471191
[TBL] [Abstract][Full Text] [Related]
9. The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.
Thomas L; Martel E; Rist W; Uphues I; Hamprecht D; Neubauer H; Augustin R
Diabetes Obes Metab; 2024 Jun; 26(6):2368-2378. PubMed ID: 38560764
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-like peptides-1 from phylogenetically ancient fish show potent anti-diabetic activities by acting as dual GLP1R and GCGR agonists.
Graham GV; Conlon JM; Abdel-Wahab YH; Flatt PR
Mol Cell Endocrinol; 2019 Jan; 480():54-64. PubMed ID: 30312651
[TBL] [Abstract][Full Text] [Related]
12. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
[TBL] [Abstract][Full Text] [Related]
13. Identification of potent 11mer glucagon-like peptide-1 receptor agonist peptides with novel C-terminal amino acids: Homohomophenylalanine analogs.
Haque TS; Lee VG; Riexinger D; Lei M; Malmstrom S; Xin L; Han S; Mapelli C; Cooper CB; Zhang G; Ewing WR; Krupinski J
Peptides; 2010 May; 31(5):950-5. PubMed ID: 20138099
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of oxyntomodulin and GLP-1 on glucose metabolism.
Du X; Kosinski JR; Lao J; Shen X; Petrov A; Chicchi GG; Eiermann GJ; Pocai A
Am J Physiol Endocrinol Metab; 2012 Jul; 303(2):E265-71. PubMed ID: 22621866
[TBL] [Abstract][Full Text] [Related]
15. Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys.
Elvert R; Bossart M; Herling AW; Weiss T; Zhang B; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Keil S; Lorenz M; Lorenz K; Riz M; Hennerici W; Larsen PJ
Endocrinology; 2018 Aug; 159(8):3105-3119. PubMed ID: 29992313
[TBL] [Abstract][Full Text] [Related]
16. Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist.
Pickford P; Lucey M; Rujan RM; McGlone ER; Bitsi S; Ashford FB; Corrêa IR; Hodson DJ; Tomas A; Deganutti G; Reynolds CA; Owen BM; Tan TM; Minnion J; Jones B; Bloom SR
Mol Metab; 2021 Sep; 51():101242. PubMed ID: 33933675
[TBL] [Abstract][Full Text] [Related]
17. Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice.
Patel V; Joharapurkar A; Dhanesha N; Kshirsagar S; Patel K; Bahekar R; Shah G; Jain M
Can J Physiol Pharmacol; 2013 Dec; 91(12):1009-15. PubMed ID: 24289070
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors.
Darbalaei S; Yuliantie E; Dai A; Chang R; Zhao P; Yang D; Wang MW; Sexton PM; Wootten D
Biochem Pharmacol; 2020 Oct; 180():114150. PubMed ID: 32682761
[TBL] [Abstract][Full Text] [Related]
19. The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies.
Jiang P; Zeng Y; Yang W; Li L; Zhou L; Xiao L; Li Y; Gu B; Li X; Li J; Li W; Guo L
Biomed Pharmacother; 2024 May; 174():116485. PubMed ID: 38518602
[TBL] [Abstract][Full Text] [Related]
20. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
Finan B; Ma T; Ottaway N; Müller TD; Habegger KM; Heppner KM; Kirchner H; Holland J; Hembree J; Raver C; Lockie SH; Smiley DL; Gelfanov V; Yang B; Hofmann S; Bruemmer D; Drucker DJ; Pfluger PT; Perez-Tilve D; Gidda J; Vignati L; Zhang L; Hauptman JB; Lau M; Brecheisen M; Uhles S; Riboulet W; Hainaut E; Sebokova E; Conde-Knape K; Konkar A; DiMarchi RD; Tschöp MH
Sci Transl Med; 2013 Oct; 5(209):209ra151. PubMed ID: 24174327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
